secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-105923
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem posts $11.2M Q3 product revenue, GAAP net loss $98.5M
--------------------------------------------------------------

- AVMAPKI FAKZYNJA CO-PACK achieved $11.2 million net product revenue in first full quarter of launch.
- GAAP net loss $98.5M ($1.35/share) vs $24.0M ($0.60) YoY; non-GAAP adjusted net loss $39.4M ($0.54/share).
- Cash $137.7M; with product revenue and warrant exercises, runway into H2 2026.
- VS-7375 cleared 400 mg and 600 mg QD monotherapy with no DLTs; no nausea/vomiting/diarrhea >Grade 1.
- RAMP 301 (LGSOC) completed targeted enrollment of 270 patients early; IDMC recommended 29 additional patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/0001104659-25-105923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer